Compass Therapeutics (CMPX) Change in Accured Expenses (2018 - 2026)

Compass Therapeutics has disclosed Change in Accured Expenses across 9 years of filings, most recently posting -$3.4 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$3.4 million, down 148.84% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.2 million (down 145.74% YoY), and the FY2025 annual result was $5.1 million, up 35.06% from the prior year.
• Change in Accured Expenses came in at -$3.4 million for Q1 2026 at Compass Therapeutics, down from $2.7 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $6.9 million in Q1 2025 to a low of -$5.4 million in Q2 2022.
• The 5-year median for Change in Accured Expenses is -$1.1 million (2023), against an average of -$45588.2.
• Across the five-year window, Change in Accured Expenses slumped 12354.55% in 2022 and jumped 1090.99% in 2025, its largest moves.
• Compass Therapeutics' Change in Accured Expenses stood at $5.9 million in 2022, then slumped by 152.62% to -$3.1 million in 2023, then jumped by 207.7% to $3.4 million in 2024, then retreated by 19.93% to $2.7 million in 2025, then plunged by 225.34% to -$3.4 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.4 million (Q1 2026), $2.7 million (Q4 2025), and -$2.3 million (Q3 2025), per Business Quant data.